Start-Up Quarterly Statistics, Q1 2013
This article was originally published in Start Up
Executive Summary
Start-up company fundraising got off to a slow start in 2013: life sciences companies brought in $398.7 million, roughly 59% less than in the final quarter of 2012. Of the total raised, 84% went to biopharmas. The majority of start-up alliances were for discovery- or preclinical-stage products and there were four start-up acquisitions for the quarter – three in biopharma and one in the medical device sector.
You may also be interested in...
AstraZeneca Bets Big On Moderna’s Preclinical Messenger RNA Technology
The struggling pharma pays $240 million upfront for an exclusive collaboration to discover, develop and commercialize mRNA drugs in the cardiovascular, metabolic, renal and oncology spaces.
Resolve Scores The Option Of An Exit With Takeda Tie-Up
Resolve Therapeutics and Takeda Pharmaceuticals have agreed to an option agreement that will add to the Japanese pharma’s immunology pipeline while also providing a path to an eventual exit for the biotech’s investors.
RQx Antibiotic Collaboration With Genentech Marks Third Exit For Avalon Ventures This Year
Avalon-backed RQx will team with Genentech to discover and develop antibiotics against a novel, undisclosed target. The deal essentially is an exit for hybrid VC firm Avalon, which already has exit deals this year with BioMarin and Genentech.